earnings
confidence high
sentiment neutral
materiality 0.75
PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
2025-Q3 EPS reported
-$1.69
revenue$115,360,000
- GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).
- Consumable revenue record $21.3M (+15% YoY); instrument revenue $11.3M (down 33% YoY).
- Non-GAAP gross margin improved to 42% from 33% YoY; operating expenses cut to $53.9M from $62.4M.
- Revio systems shipped 13 (vs 22); Vega systems shipped 32; cash and investments $298.7M.
- Launched SPRQ-Nx chemistry to reduce sequencing costs up to 40%; Sequel II CNDx approved in China.